Therefore, co-delivery of Cas9-NLRP3 and Dex could significantly alleviate the symptoms of psoriasis and improve overall inflammatory activity compared to the single treatment with Cas9-NLRP3 or Dex (83). Here, NLRP3 is linked to psoriasis.